BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 23987996)

  • 1. Serpins as therapeutics--a potential biologic source for unique protein-based therapeutics.
    Lucas A
    Cardiovasc Hematol Disord Drug Targets; 2013 Aug; 13(2):89. PubMed ID: 23987996
    [No Abstract]   [Full Text] [Related]  

  • 2. Anti-apoptotic serpins as therapeutics in cardiovascular diseases.
    Kuiper J; Quax PH; Bot I
    Cardiovasc Hematol Disord Drug Targets; 2013 Aug; 13(2):111-22. PubMed ID: 23987999
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The serpin solution; targeting thrombotic and thrombolytic serine proteases in inflammation.
    Chen H; Davids JA; Zheng D; Bryant M; Bot I; van Berckel TJ; Biessen E; Pepine C; Ryman K; Progulski-Fox A; Kesavalu L; Moyer R; McFadden G; Lucas A
    Cardiovasc Hematol Disord Drug Targets; 2013 Aug; 13(2):99-110. PubMed ID: 23987998
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The serpin saga; development of a new class of virus derived anti-inflammatory protein immunotherapeutics.
    Lucas A; Liu L; Dai E; Bot I; Viswanathan K; Munuswamy-Ramunujam G; Davids JA; Bartee MY; Richardson J; Christov A; Wang H; Macaulay C; Poznansky M; Zhong R; Miller L; Biessen E; Richardson M; Sullivan C; Moyer R; Hatton M; Lomas DA; McFadden G
    Adv Exp Med Biol; 2009; 666():132-56. PubMed ID: 20054981
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Viral-derived Serp-1 as an adjunctive therapy for percutaneous coronary intervention: another not ready for prime time player?
    Leopold JA
    Circ Cardiovasc Interv; 2010 Dec; 3(6):528-30. PubMed ID: 21156927
    [No Abstract]   [Full Text] [Related]  

  • 6. Can a viral serine proteinase inhibitor prevent postangioplasty restenosis?
    Haber E
    Circulation; 1996 Dec; 94(11):2694-5. PubMed ID: 8941089
    [No Abstract]   [Full Text] [Related]  

  • 7. Serpins for diagnosis and therapy in cancer.
    Zheng D; Chen H; Davids J; Bryant M; Lucas A
    Cardiovasc Hematol Disord Drug Targets; 2013 Aug; 13(2):123-32. PubMed ID: 23988000
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacology and pharmacokinetics of LEX 032, a bioengineered serpin: the first of a potential new class of drugs.
    Sands H; Hook JB
    Drug Metab Rev; 1997; 29(1-2):309-28. PubMed ID: 9187523
    [No Abstract]   [Full Text] [Related]  

  • 9. Novel perspectives in clinical cardiology and cardiac surgery.
    Mihailidou AS
    Future Cardiol; 2014 Nov; 10(6):677-8. PubMed ID: 25495807
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Protease Inhibitors in Tick Saliva: The Role of Serpins and Cystatins in Tick-host-Pathogen Interaction.
    Chmelař J; Kotál J; Langhansová H; Kotsyfakis M
    Front Cell Infect Microbiol; 2017; 7():216. PubMed ID: 28611951
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Viral serine protease inhibitors as anti-atherosclerotic therapy.
    Bot I; van Berkel TJ; Biessen EA
    Curr Opin Investig Drugs; 2007 Sep; 8(9):729-35. PubMed ID: 17729184
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A randomized controlled, phase 2 trial of the viral serpin Serp-1 in patients with acute coronary syndromes undergoing percutaneous coronary intervention.
    Tardif JC; L'Allier PL; Grégoire J; Ibrahim R; McFadden G; Kostuk W; Knudtson M; Labinaz M; Waksman R; Pepine CJ; Macaulay C; Guertin MC; Lucas A
    Circ Cardiovasc Interv; 2010 Dec; 3(6):543-8. PubMed ID: 21062996
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recombinant elastase inhibitors for therapy.
    Schnebli HP
    Ann N Y Acad Sci; 1991; 624():212-8. PubMed ID: 1676575
    [No Abstract]   [Full Text] [Related]  

  • 14. Viral serine proteinase inhibitor (SERP-1) effectively decreases the incidence of graft vasculopathy in heterotopic heart allografts.
    Hausen B; Boeke K; Berry GJ; Morris RE
    Transplantation; 2001 Aug; 72(3):364-8. PubMed ID: 11502962
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Amelioration of antigen induced arthritis in rabbits treated with a secreted viral serine proteinase inhibitor.
    Maksymowych WP; Nation N; Nash P; Macen J; Lucas A; McFadden G; Russell AS
    J Rheumatol; 1996 May; 23(5):878-82. PubMed ID: 8724302
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serine protease inhibitors: pathological and therapeutic insights.
    Miyata T
    Bull Mem Acad R Med Belg; 2006; 161(5):292-300; discussion 300-1. PubMed ID: 17283901
    [No Abstract]   [Full Text] [Related]  

  • 17. Elastase inhibitor for detection and treatment of inflammation and infection.
    Fricker J
    Mol Med Today; 1998 Jan; 4(1):5. PubMed ID: 9494959
    [No Abstract]   [Full Text] [Related]  

  • 18. [Serine protease inhibitors (serpins); regulators of coagulation and inflammation reactions with therapeutic potential].
    Hack CE; Abbink JJ; Nuijens JH
    Ned Tijdschr Geneeskd; 1990 May; 134(21):1035-9. PubMed ID: 2195358
    [No Abstract]   [Full Text] [Related]  

  • 19. Natural proteinaceous inhibitors of serine proteases.
    Debowski D
    Curr Pharm Des; 2013; 19(6):1068-84. PubMed ID: 23016680
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cardioprotection by a novel recombinant serine protease inhibitor in myocardial ischemia and reperfusion injury.
    Murohara T; Guo JP; Lefer AM
    J Pharmacol Exp Ther; 1995 Sep; 274(3):1246-53. PubMed ID: 7562495
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.